Cardiovascular DiseasesNCT00005134
Strong Heart Study
An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
Trial summary
To determine morbidity and mortality from cardiovascular disease among American Indians and to compare cardiovascular disease risk factor levels among Indian groups living in different geographic areas. Read more about this study
- Who is it for?
- Ages 45 to 74 years
- Conditions the study is for
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Sep 1988to Dec 2005
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
No eligibility criteria
About this study
To determine morbidity and mortality from cardiovascular disease among American Indians and to compare cardiovascular disease risk factor levels among Indian groups living in different geographic areas.
Read the detailed description
BACKGROUND:
Available data indicate that cardiovascular disease has become the leading cause of death in American Indians. Some Indian groups appear to be participating in the decline in cardiovascular disease rates occurring within the overall United States population, but, among other Indians, rates appear to be increasing. In addition, there appears to be excessive mortality attributed to cardiovascular disease in younger Indians.
Several problems have made it difficult to obtain adequate data on the prevalence and severity of cardiovascular disease as a health problem among American Indians. The small size, relatively young age, cultural and anthropological diversity and the geographic dispersion of the American Indian population have made it impractical to examine large numbers of subjects for research and vital statistics surveys. Excess mortality among younger Indians from noncardiovascular causes may have obscured the true risk of cardiovascular disease in this population. Definitions of the term 'Indian' are variable in published reports. The denominators from which disease rates were calculated often were based on uncertain estimates of the population at risk. Definitions of disease and methods of its ascertainment have varied in different studies. In addition, health care services available to Indians vary considerably in different geographic areas, and possibly contribute to differences in reported morbidity and mortality.
States with the largest Indian populations are Arizona, Oklahoma, California, New Mexico and North Carolina. Because the major concentrations of Indian tribal groups in the United States are located in the Southwest, more than half of the reported studies of cardiovascular disease and cardiovascular disease risk factors have been conducted in these groups. Studies have been reported in the Pima, Papago, Navajo, Apache, Hopi and other tribes in the Arizona and New Mexico region. In general, these studies have concluded that cardiovascular disease rates are lower in these Indian groups than in the United States population.
The etiology, manifestations and natural history of cardiovascular disease among Indians are not well known. Current information indicates 43 percent of heart disease deaths among Native Americans are secondary to myocardial infarction and 32 percent are due to chronic ischemic heart disease. Below the age of 35 years, the heart disease death rate in Native Americans exceeded reported United States rates. A significant portion of this excess may be due to congenital heart disease.
Limited data are available on current levels and time related changes in risk factors for ischemic cardiovascular disease among American Indians. Because of the absence of systematic surveys of defined populations and the lack of standardization of methodology employed in studies of different groups, it is difficult to interpret apparent increases in risk factors over time or to explain apparent differences in cardiovascular disease rates by differences in risk factor distributions. Studies of current risk factor levels and distributions are of great importance, however, since they may provide the best estimates of the future relative risk of cardiovascular disease within the Indian population.
Multiple factors may contribute to current risk factor levels in American Indians. Variations may exist among tribal groups, secondary to genetic admixture and to both the degree and duration of acculturation and in relation to attained socioeconomic status. It is important to recognize that generalizations about risk factors for cardiovascular disease in American Indians are inappropriate and that available data only apply to groups with similar origins and history.
The study was recommended by the Subcommittee on Cardiovascular and Cerebrovascular Disease of the Secretary of Health and Human Services Task force on Black and Minority Health in 1986 and was approved by the National Heart, Lung, and Blood Advisory Council in May 1987. The Request for Applications was released in October 1987 with awards made in September 1988. The study was renewed and expanded twice.
DESIGN NARRATIVE:
The study is conducted on defined populations of Indians living on reservations and involves two components: a review of death certificates and health care records: and a population survey of the prevalence of and risk factors for cardiovascular disease. The population survey phase consists of three examinations for cardiovascular disease risk factors, clinical cardiac disease, and the use of medical services for cardiovascular disease care. Elisa Lee of the University of Oklahoma is studying members of the seven tribes of Oklahoma. Thomas Welty at the Aberdeen Area Indian Health Service follows three Northern Sioux tribes. Barbara Howard of Medlantic studies Pima Indians from the Gila River and Salt River Indian communities.
After the initial three years the Strong Heart Study was renewed to: extend surveillance of the community for mortality; and to reexamine the cohort after an approximate four year interval to assess the development of cardiovascular disease and change in CVD risk factors. Echocardiography and pulmonary function testing were added to the examination protocol for the second examination. In 1996 the study was funded to continue the follow-up for morbidity and mortality and to complete a third examination of the study cohort. New measures added to the third exam included measures of carotid atherosclerosis, arterial stiffness, a substudy of asthma, and a family study pilot. The third examination of the cohort was completed in August, 1999 with 3,200 members reexamined. In addition, more than 560 participants were included in the substudy of asthma. There have been approximately 1,000 deaths among cohort members in the 12 years since the initial examination.
Phase IV of the study began in FY 2000 for a five-year extension to expand the family study and to continue morbidity and mortality surveillance of the original cohort. Each of the three field centers will recruit an additional 900 participants who are members of families containing at least two SHS cohort members. Furthermore, the pilot study family members will be invited to a follow-up exam after the 900 members are enrolled at each center. The Phase IV family study exams will include cardiac and carotid ultrasound exams, blood pressures, noninvasive measurements of arterial stiffness (tonometry), ECGs, anthropometry, medical history, behavioral assessments (socio-economic status, diet, smoking, alcohol, and physical activity), blood chemistries, lipids, and DNA. The specific aims of the Phase IV study are to expand the family study to increase the power for genetic analyses, to continue surveillance of the original cohort to ascertain more CVD cases, to investigate the association of some pertinent biomarkers and cardiac functions with the development of CVD, and to initiate mortality surveillance in the family members.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provided funding for a gallstone component.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Asthma, Carotid Artery Diseases, Coronary Disease
- Medical subject headings
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Asthma, Carotid Artery Diseases, Coronary Disease, Hypercholesterolemia, Hypertension
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2000 (estimated)
- Study startSep 1988
- Primary completionDec 2005
- Study completionDec 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by National Heart, Lung, and Blood Institute (NHLBI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Investigators
- Lyle Best, U.S. P.H.S. Aberdeen Area Indian Health ServicesRichard Devereux, Weill Medical College of Cornell UniversityBarbara Howard, Medlantic Research FoundationElisa Lee, University of OklahomaJean MacCluer, Southwest Foundation for Biomedical Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005134
- Sponsor's protocol ID
- 1004
- Other IDs
- U01HL065520
- Status last verified
- May 2009
- First submitted
- 25 May 2000
- Last updated
- 29 Jul 2016
- Results posted
- No
Publications
Please refer to the Strong Heart Study Home Page for complete bibliography. http://strongheart.ouhsc.edu/
Fretts AM, Jensen PN, Sitlani CM, Hoofnagle A, Lidgard B, Umans JG, Siscovick DS, King IB, Howard BV, Cole SA, Lemaitre RN. Circulating Sphingolipids and All-Cause Mortality: The Strong Heart Family Study. J Am Heart Assoc. 2024 Jul 2;13(13):e032536. doi: 10.1161/JAHA.123.032536. Epub 2024 Jun 21.
PubMed 38904223Fretts AM, Jensen PN, Hoofnagle A, McKnight B, Howard BV, Umans J, Yu C, Sitlani C, Siscovick DS, King IB, Sotoodehnia N, Lemaitre RN. Plasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study. J Nutr. 2020 May 1;150(5):1214-1222. doi: 10.1093/jn/nxz259.
PubMed 31665380Mancusi C, de Simone G, Best LG, Wang W, Zhang Y, Roman MJ, Lee ET, Howard BV, Devereux RB. Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the Strong Heart Study cohort. Cardiovasc Diabetol. 2019 Apr 30;18(1):56. doi: 10.1186/s12933-019-0862-9.
PubMed 31039789Lemaitre RN, Yu C, Hoofnagle A, Hari N, Jensen PN, Fretts AM, Umans JG, Howard BV, Sitlani CM, Siscovick DS, King IB, Sotoodehnia N, McKnight B. Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study. Diabetes. 2018 Aug;67(8):1663-1672. doi: 10.2337/db17-1449. Epub 2018 Mar 27.
PubMed 29588286de Simone G, Wang W, Best LG, Yeh F, Izzo R, Mancusi C, Roman MJ, Lee ET, Howard BV, Devereux RB. Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol. 2017 May 12;16(1):64. doi: 10.1186/s12933-017-0542-6.
PubMed 28499385
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Strong Heart Study
- ClinicalTrials.gov ID
- NCT00005134
- Acronym / sponsor ID
- 1004
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Asthma, Carotid Artery Diseases, Coronary Disease
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)US National Institutes of Health
- Study start
- Sep 1988
- Primary completion
- Dec 2005 (actual)
- Study completion
- Dec 2005 (actual)
- First posted
- 26 May 2000 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine morbidity and mortality from cardiovascular disease among American Indians and to compare cardiovascular disease risk factor levels among Indian groups living in different geographic areas.
Detailed description
BACKGROUND:
Available data indicate that cardiovascular disease has become the leading cause of death in American Indians. Some Indian groups appear to be participating in the decline in cardiovascular disease rates occurring within the overall United States population, but, among other Indians, rates appear to be increasing. In addition, there appears to be excessive mortality attributed to cardiovascular disease in younger Indians.
Several problems have made it difficult to obtain adequate data on the prevalence and severity of cardiovascular disease as a health problem among American Indians. The small size, relatively young age, cultural and anthropological diversity and the geographic dispersion of the American Indian population have made it impractical to examine large numbers of subjects for research and vital statistics surveys. Excess mortality among younger Indians from noncardiovascular causes may have obscured the true risk of cardiovascular disease in this population. Definitions of the term 'Indian' are variable in published reports. The denominators from which disease rates were calculated often were based on uncertain estimates of the population at risk. Definitions of disease and methods of its ascertainment have varied in different studies. In addition, health care services available to Indians vary considerably in different geographic areas, and possibly contribute to differences in reported morbidity and mortality.
States with the largest Indian populations are Arizona, Oklahoma, California, New Mexico and North Carolina. Because the major concentrations of Indian tribal groups in the United States are located in the Southwest, more than half of the reported studies of cardiovascular disease and cardiovascular disease risk factors have been conducted in these groups. Studies have been reported in the Pima, Papago, Navajo, Apache, Hopi and other tribes in the Arizona and New Mexico region. In general, these studies have concluded that cardiovascular disease rates are lower in these Indian groups than in the United States population.
The etiology, manifestations and natural history of cardiovascular disease among Indians are not well known. Current information indicates 43 percent of heart disease deaths among Native Americans are secondary to myocardial infarction and 32 percent are due to chronic ischemic heart disease. Below the age of 35 years, the heart disease death rate in Native Americans exceeded reported United States rates. A significant portion of this excess may be due to congenital heart disease.
Limited data are available on current levels and time related changes in risk factors for ischemic cardiovascular disease among American Indians. Because of the absence of systematic surveys of defined populations and the lack of standardization of methodology employed in studies of different groups, it is difficult to interpret apparent increases in risk factors over time or to explain apparent differences in cardiovascular disease rates by differences in risk factor distributions. Studies of current risk factor levels and distributions are of great importance, however, since they may provide the best estimates of the future relative risk of cardiovascular disease within the Indian population.
Multiple factors may contribute to current risk factor levels in American Indians. Variations may exist among tribal groups, secondary to genetic admixture and to both the degree and duration of acculturation and in relation to attained socioeconomic status. It is important to recognize that generalizations about risk factors for cardiovascular disease in American Indians are inappropriate and that available data only apply to groups with similar origins and history.
The study was recommended by the Subcommittee on Cardiovascular and Cerebrovascular Disease of the Secretary of Health and Human Services Task force on Black and Minority Health in 1986 and was approved by the National Heart, Lung, and Blood Advisory Council in May 1987. The Request for Applications was released in October 1987 with awards made in September 1988. The study was renewed and expanded twice.
DESIGN NARRATIVE:
The study is conducted on defined populations of Indians living on reservations and involves two components: a review of death certificates and health care records: and a population survey of the prevalence of and risk factors for cardiovascular disease. The population survey phase consists of three examinations for cardiovascular disease risk factors, clinical cardiac disease, and the use of medical services for cardiovascular disease care. Elisa Lee of the University of Oklahoma is studying members of the seven tribes of Oklahoma. Thomas Welty at the Aberdeen Area Indian Health Service follows three Northern Sioux tribes. Barbara Howard of Medlantic studies Pima Indians from the Gila River and Salt River Indian communities.
After the initial three years the Strong Heart Study was renewed to: extend surveillance of the community for mortality; and to reexamine the cohort after an approximate four year interval to assess the development of cardiovascular disease and change in CVD risk factors. Echocardiography and pulmonary function testing were added to the examination protocol for the second examination. In 1996 the study was funded to continue the follow-up for morbidity and mortality and to complete a third examination of the study cohort. New measures added to the third exam included measures of carotid atherosclerosis, arterial stiffness, a substudy of asthma, and a family study pilot. The third examination of the cohort was completed in August, 1999 with 3,200 members reexamined. In addition, more than 560 participants were included in the substudy of asthma. There have been approximately 1,000 deaths among cohort members in the 12 years since the initial examination.
Phase IV of the study began in FY 2000 for a five-year extension to expand the family study and to continue morbidity and mortality surveillance of the original cohort. Each of the three field centers will recruit an additional 900 participants who are members of families containing at least two SHS cohort members. Furthermore, the pilot study family members will be invited to a follow-up exam after the 900 members are enrolled at each center. The Phase IV family study exams will include cardiac and carotid ultrasound exams, blood pressures, noninvasive measurements of arterial stiffness (tonometry), ECGs, anthropometry, medical history, behavioral assessments (socio-economic status, diet, smoking, alcohol, and physical activity), blood chemistries, lipids, and DNA. The specific aims of the Phase IV study are to expand the family study to increase the power for genetic analyses, to continue surveillance of the original cohort to ascertain more CVD cases, to investigate the association of some pertinent biomarkers and cardiac functions with the development of CVD, and to initiate mortality surveillance in the family members.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provided funding for a gallstone component.
Study design
Who may qualify
- Ages
- 45 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2016.
- BackgroundPlease refer to the Strong Heart Study Home Page for complete bibliography. http://strongheart.ouhsc.edu/
- Derived from this study: PubMed 38904223Fretts AM, Jensen PN, Sitlani CM, Hoofnagle A, Lidgard B, Umans JG, Siscovick DS, King IB, Howard BV, Cole SA, Lemaitre RN. Circulating Sphingolipids and All-Cause Mortality: The Strong Heart Family Study. J Am Heart Assoc. 2024 Jul 2;13(13):e032536. doi: 10.1161/JAHA.123.032536. Epub 2024 Jun 21.
- Derived from this study: PubMed 31665380Fretts AM, Jensen PN, Hoofnagle A, McKnight B, Howard BV, Umans J, Yu C, Sitlani C, Siscovick DS, King IB, Sotoodehnia N, Lemaitre RN. Plasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study. J Nutr. 2020 May 1;150(5):1214-1222. doi: 10.1093/jn/nxz259.
- Derived from this study: PubMed 31039789Mancusi C, de Simone G, Best LG, Wang W, Zhang Y, Roman MJ, Lee ET, Howard BV, Devereux RB. Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the Strong Heart Study cohort. Cardiovasc Diabetol. 2019 Apr 30;18(1):56. doi: 10.1186/s12933-019-0862-9.
- Derived from this study: PubMed 29588286Lemaitre RN, Yu C, Hoofnagle A, Hari N, Jensen PN, Fretts AM, Umans JG, Howard BV, Sitlani CM, Siscovick DS, King IB, Sotoodehnia N, McKnight B. Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study. Diabetes. 2018 Aug;67(8):1663-1672. doi: 10.2337/db17-1449. Epub 2018 Mar 27.
- Derived from this study: PubMed 28499385de Simone G, Wang W, Best LG, Yeh F, Izzo R, Mancusi C, Roman MJ, Lee ET, Howard BV, Devereux RB. Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol. 2017 May 12;16(1):64. doi: 10.1186/s12933-017-0542-6.
- Related InfoLink provided by the sponsor.
Related trials for Cardiovascular Diseases
RecruitingPhase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2/3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Heart Failure, Left Ventricular Systolic Dysfunction
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Active, not recruitingPhase 4
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Coronary Artery Disease
Active, not recruiting
VOLT CE Mark Study
Atrial Arrhythmia, Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lyle Best
U.S. P.H.S. Aberdeen Area Indian Health Services
Richard Devereux
Weill Medical College of Cornell University
Barbara Howard
Medlantic Research Foundation
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00005134, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2016.